Your browser doesn't support javascript.
Anti-IL-17 monoclonal antibodies in hospitalized patients with severe COVID-19: A pilot study.
Avdeev, Sergey N; Trushenko, Natalia V; Tsareva, Natalia A; Yaroshetskiy, Andrey I; Merzhoeva, Zamira M; Nuralieva, Galia S; Nekludova, Galina V; Chikina, Svetlana Yu; Gneusheva, Tatiana Yu; Suvorova, Olga A; Shmidt, Anna E.
  • Avdeev SN; Department of Pulmonology, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia. Electronic address: serg_avdeev@list.ru.
  • Trushenko NV; Department of Pulmonology, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
  • Tsareva NA; Department of Pulmonology, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
  • Yaroshetskiy AI; Department of Pulmonology, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
  • Merzhoeva ZM; Department of Pulmonology, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
  • Nuralieva GS; Department of Pulmonology, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
  • Nekludova GV; Department of Pulmonology, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
  • Chikina SY; Department of Pulmonology, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
  • Gneusheva TY; Department of Pulmonology, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
  • Suvorova OA; International School 'Medicine of the Future', I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
  • Shmidt AE; International School 'Medicine of the Future', I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
Cytokine ; 146: 155627, 2021 10.
Article in English | MEDLINE | ID: covidwho-1293702
ABSTRACT

BACKGROUND:

One of the main pathophysiological mechanisms underlying the severe course of COVID-19 is the hyper-inflammatory syndrome associated with progressive damage of lung tissue and multi-organ dysfunction. IL-17 has been suggested to be involved in hyper-inflammatory syndrome.

OBJECTIVE:

To evaluate the efficacy and safety of the IL-17 inhibitor netakimab in patients with severe COVID-19. STUDY

DESIGN:

In our retrospective case-control study we evaluated the efficacy of netakimab in hospitalized patients with severe COVID-19 outside the intensive care unit (ICU). Patients in the experimental group were treated with standard of care therapy and netakimab at a dose of 120 mg subcutaneously.

RESULTS:

171 patients with severe COVID-19 were enrolled in our study, and 88 of them received netakimab. On the 3 day of therapy, body temperature, SpO2/FiO2, NEWS2 score, and CRP improved significantly in the netakimab group compared to the control group. Other clinical outcomes such as transfer to ICU (11.4% vs 9.6%), need for mechanical ventilation (10.2% vs 9.6%), 28-day mortality (10.2% vs 8.4%), did not differ between the groups.

CONCLUSION:

In hospitalized patients with severe COVID-19, anti-IL-17 therapy might mitigate the inflammatory response and improve oxygenation, but do not affect the need for mechanical ventilation and mortality.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Interleukin-17 / Antibodies, Monoclonal, Humanized / SARS-CoV-2 / COVID-19 / Hospitalization / Inpatients Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid Limits: Aged / Female / Humans / Male / Middle aged Language: English Journal: Cytokine Journal subject: Allergy and Immunology Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Interleukin-17 / Antibodies, Monoclonal, Humanized / SARS-CoV-2 / COVID-19 / Hospitalization / Inpatients Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid Limits: Aged / Female / Humans / Male / Middle aged Language: English Journal: Cytokine Journal subject: Allergy and Immunology Year: 2021 Document Type: Article